Lista de obras -

Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets.

artículo científico publicado en 2013

Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain.

artículo científico publicado en 2008

Analysis of Human Biologics With a Mouse Skin Transplant Model in Humanized Mice ⬇️

artículo científico publicado el 17 de agosto de 2012

Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.

artículo científico publicado en 2017

Continuous glucose monitoring: long live the revolution!

artículo científico publicado en 2008

Dress and address: patient preferences regarding doctor's style of dress and patient interaction.

artículo científico publicado en 2008

Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).

artículo científico publicado en 2015

Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cellsin vivo

artículo científico publicado en 2003

Genetic analysis of the 3' untranslated region of the tumour necrosis factor shows a highly conserved region in rheumatoid arthritis affected and unaffected subjects.

artículo científico publicado en 1999

Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.

artículo científico publicado en 1996

High bone turnover in Irish professional jockeys.

artículo científico publicado en 2009

Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.

artículo científico publicado en 2017

Humanized mice as a model for aberrant responses in human T cell immunotherapy.

artículo científico publicado en 2014

Immunological biomarkers: catalysts for translational advances in autoimmune diabetes

artículo científico publicado en 2013

Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

scientific article published on June 2011

In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment.

artículo científico publicado en 2017

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

artículo científico publicado en 2017

New and future immunomodulatory therapy in type 1 diabetes ⬇️

artículo científico publicado el 17 de febrero de 2012

Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study

artículo científico publicado en 2015

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

artículo científico publicado en 2014

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

artículo científico publicado en 2016

Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma

artículo científico publicado en 2012

Self-monitoring of blood glucose did not improve glycaemic control in patients with type 2 diabetes not treated with insulin.

artículo científico publicado en 2008

Simulation work in adaptive dose-finding designs to identify dose-intervals that achieve targets in multiple endpoints.

artículo científico publicado en 2015

Targeting regulatory T cells with Interleukin-2 treatment in type 1 diabetes: a response-adaptive, non-randomised, open-label trial of repeat doses of Aldesleukin (DILfrequency)

Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

artículo científico publicado en 2012

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial ⬇️

artículo científico publicado el 21 de octubre de 2012

When a nephrectomy cures hypoglycaemia ⬇️

artículo científico publicado el 17 de mayo de 2009

Lista de obras de

Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets.

Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain.

Analysis of Human Biologics With a Mouse Skin Transplant Model in Humanized Mice ⬇️

Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.

Continuous glucose monitoring: long live the revolution!

Dress and address: patient preferences regarding doctor's style of dress and patient interaction.

Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).

Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cellsin vivo

Genetic analysis of the 3' untranslated region of the tumour necrosis factor shows a highly conserved region in rheumatoid arthritis affected and unaffected subjects.

Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.

High bone turnover in Irish professional jockeys.

Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.

Humanized mice as a model for aberrant responses in human T cell immunotherapy.

Immunological biomarkers: catalysts for translational advances in autoimmune diabetes

Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment.

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

New and future immunomodulatory therapy in type 1 diabetes ⬇️

Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma

Self-monitoring of blood glucose did not improve glycaemic control in patients with type 2 diabetes not treated with insulin.

Simulation work in adaptive dose-finding designs to identify dose-intervals that achieve targets in multiple endpoints.

Targeting regulatory T cells with Interleukin-2 treatment in type 1 diabetes: a response-adaptive, non-randomised, open-label trial of repeat doses of Aldesleukin (DILfrequency)

Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial ⬇️

When a nephrectomy cures hypoglycaemia ⬇️